


CURRICULUM VITAE



Nelson Jen An Chao

05/04/2014

PERSONAL INFORMATION

Business Address: Duke University Medical Center
Division of Cellular Therapy/BMT
Box 3961
Durham, North Carolina 27710

Overnight mailing: Duke University Medical Center
2400 Pratt Street, Suite 9100
Durham, NC 27705

Business Telephone: (919) 668-1011
Business FAX: (919) 668-1091
email: chao0002@mc.duke.edu

Home Address: 2408 Vintage Hill Drive
Durham, NC 27712

Home Telephone: (919) 908-1749

Nationality: U.S.A.

EDUCATION

1973 High School, Sao Paulo, Brazil
1977 B.A. cum laude, Harvard University, Cambridge, Massachusetts
1981 M.D. with honors, Yale University, New Haven, Connecticut
2000 M.B.A., Duke University, Durham, North Carolina

POSTGRADUATE MEDICAL TRAINING

1981-1984 Resident in Medicine, Stanford University Medical Center, Stanford, CA
1984 Internist, Menlo Medical Clinic, Menlo Park, CA
1985 Visiting Lecturer, University of Hong Kong-Queen Mary Hospital
1986 American Cancer Society Fellow, Stanford University, Stanford, CA
1985-1988 Fellow in Oncology, Stanford University Medical Center, Stanford, CA

POSITIONS

1989-1990 Physician Specialist, Bone Marrow Transplantation Program,
Stanford University Medical Center, Stanford, CA
1989-1996 Assistant Director, Director, Outpatient Clinic Bone Marrow
Transplantation Program Stanford University Medical Center, Stanford, CA
1991 - 1996 Assistant Professor of Medicine, Bone Marrow Transplantation Program
Stanford University Medical Center, Stanford, CA
1996 - present Director, Bone Marrow Transplantation Program, Duke University, Durham, NC
1996 - 2000 Associate Professor of Medicine, Duke University, Durham, NC
1998 Acting Chief, Medical Oncology, Duke University, Durham, NC

2000 - 2012 Co-founder, Aldagen, Research Triangle Park, NC
 2001 - present Co-Director, Stem Cell Laboratory, Duke University, Durham, NC
 2001 - present Professor of Medicine (tenure) & Immunology, Duke University, Durham, NC
 2004 - present Chief, Division of Cellular Therapy/BMT, Duke University, Durham, NC
 2008 - present Senior Leadership Council, Duke Comprehensive Cancer Center
 2010 - present Donald D. and Elizabeth G. Cooke Distinguished Professor
 2012 - present Co-founder C2Regenerate, Research Triangle Park, NC
 2012 – present Chief, Division of Hematological Malignancies and Cellular Therapy, Duke
 2013 – present Director of Global Cancer Program, Duke Cancer and Global Health Institutes
 2013 – present Research Professor of Global Health
 2015 Founder, International Cancer Care and Research Excellence Foundation (ICCARE)

AWARDS/HONORS

1975 Dreyfus Fellow, Harvard University
 1977 Harvard University B.A. cum laude
 1978 Yale Fellow
 1981 Yale University M.D. with honors
 1981 Alpha Omega Alpha
 1986 Timothy Becket Jr. Award for Excellence in Clinical Teaching (Voted by Stanford Housestaff)
 1994 Nycomed Prize, International Society of Pediatric Oncology Meeting (Best Presentation)
 1998 Robert and Alma Mortensen Lectureship-Texas A&M University
 1999 R. Wayne Rundles Award for Excellence in Cancer Research Duke Comprehensive Cancer Center
 2000 Best Abstract, American Society for Blood & Marrow Transplantation, 2000 Annual Meeting
 2002 Mortimer M. Bortin Award for Best Clinical Research Abstract, 2002 Tandem BMT Meeting
 2006 Elected to the Association of American Physicians (AAP)
 2011 American Society of Hematology (ASH) BLOOD Journal Top Reviewer
 2012 National Biodefense Science Board (NBSB) Voting Member
 2012 Gerhard Schmidt Lectureship, City of Hope National Cancer Center
 2012 Faculty 1000 Faculty Member of the Year, Hematology
 2014 National Preparedness and Response Science Board (NPRSB), Voting Member
 2014 Scientific Achievement Award, Chinese American Medical Society

MEMBERSHIP

1981 Alpha Omega Alpha (Yale University)
 1986 American Association for the Advancement of Science (Member).
 1987 American College of Physicians (Member).
 1990 American Society of Clinical Oncology (Member).
 1991 American Society of Hematology (Member)
 1994 American Society of Blood and Bone Marrow Transplantation (Member)
 2000 American Association of Immunologists (Member)
 2006 Association of American Physicians (Member)

LICENSURE

1982 California G47663 (inactive)
 1996 North Carolina #96-01574

BOARD CERTIFICATION

1984 American Board of Internal Medicine; Specialty: Internal Medicine (#100635)
 1987 American Board of Internal Medicine; Sub-Specialty: Oncology (#100635)

NATIONAL COMMITTEES

1993 - 1996	Diagnostic and Therapeutic Technology Assessment (DATA) panel of the American Medical Association
1994 -present	American Society of Hematology, Abstract Reviewer
1994 - 1998	American Society of Hematology, Session Chairperson
1995 - present	NCI site visit team (ad hoc member)
1995, 1996	NIH Study Section - Experimental Therapeutics - 2, ad hoc member
1995 -1998	National Marrow Donor Program - Membership and Process Improvement
1995	American Society of Blood & Bone Marrow Transplantation-Program Committee
1995	Keystone Symposia, Workshop leader
1997 – 2002	Cancer and Acute Leukemia Group B
2000 – 2001	Leukemia/Lymphoma/Myeloma Progress Review Group, NCI
2000 - 2006	Leukemia/Lymphoma Society of America Grant Review Committee
2000 – present	Gateway for Cancer Research, Grant Review Committee
2001 - 2005	Board of Scientific Councilors, NHLBI (full member), NCI (ad hoc)
2002	Program Chair, ASBMT Annual Meeting
2003 - 2005	Vice-President elect, VP and President, American Society of Blood and Marrow Transplantation
2003-2006	Lymphoma Committee, CALGB
2004 - 2008	Steering Committee, Clinical Trial Network (BMT CTN)
2005 - present	Chair, Radiation Injury Treatment Network (RITN)
2006	Principal Investigator, Centers for Medical Countermeasures against Radiation (CMCR)
2006 - 2010	Steering Committee, Immune Tolerance Network (ITN)
2007	American Society of Oncology, Scientific Review Committee
2007 – 2009	NIH Study Section – Clinical Oncology – full member
2008	American Society of Oncology, Scientific Review Committee – Track Leader
2006 - 2010	Director, ASBMT Clinical Scholars Training Course
2008 - present	Chair, Board of Scientific Councilors, Gateway for Cancer Research
2009 - present	Board Member – National Marrow Donor Program
2009 - 2013	Council Member – National Institutes of Allergy and Infectious Diseases
2012 - 2014	National Biodefense Science Board – Voting Member
2014 - 2015	National Preparedness and Response Science Board – Voting Member
2014 - present	International Cancer Experts Corps – Board of Directors

LOCAL COMMITTEES (Current)

Hematology Oncology Fellows Committee
Duke Comprehensive Cancer Center Executive & Advisory Committee
Resource Utilization Council
Cell Therapy Steering Committee
Department of Medicine Executive Board
Stem Cell Research Oversight
Chancellor's Science Council
Multiple search committees

PUBLIC SERVICE

1990 - 1996	Arbor Free Clinic, Attending Physician
1999 - 2001	Chapel Hill Soup Kitchen
2007 – 2012	Durham Project Access – Member, Board of Directors

MAJOR RESEARCH INTERESTS:

1. Graft versus host disease
2. Bone marrow transplantation
3. Stem cell biology
4. Immune reconstitution
5. Hematopoiesis
6. Mitigation of radiation effects
7. Global Health (Oncology)

EDITORIAL BOARD (current)

Biology of Blood and Marrow Transplantation (Associate Editor)
Blood
Journal of Immunology (Associate Editor)
Oncology Today (Associate Editor)
UpToDate (Section Editor)

REVIEWER

New England Journal of Medicine	Blood
Journal of Immunology	Experimental Hematology
Bone Marrow Transplantation	Science
Journal of Clinical Investigation	Leukemia
Journal of the National Cancer Institute	Journal of Clinical Oncology
Journal of Experimental Medicine	Biol Blood Marrow Transplantation
Nature Medicine	Science Translational Medicine

PEER-REVIEWED PUBLICATIONS

P-1. Yamaguchi H., Chao N. and Gershon R. Molecular composition of an antigen specific Ly-1 T suppressor inducer factor. Journal of Experimental Medicine. 155: 655-665, 1982.

P-2. Chao N., Levine J. and Horning S. Retroperitoneal fibrosis following treatment for Hodgkin's Disease. Journal of Clinical Oncology 5:231-232, 1987.

P-3. Todd J.A., Acha-Orbea H., Bell J.I., Chao N., Fronck Z., Jacob C.O., McDermott M., Sinha A., Timmerman L., Steinman L. and McDevitt H.O. A molecular basis for MHC class II - associated autoimmunity. Science 240:1003-1009, 1988.

P-4. Chao N., Jacob C., Timmerman, L. and McDevitt, H.O. Molecular characterization of class II (B1 domain) antigen in the BB diabetes prone and resistant rat. Immunogenetics 29:231-234, 1989.

P-5. Schmidt-Wolf I, Aihara M, Negrin R, Blume KG and Chao NJ. Restoration of lymphokine activated killer cell activity after cryopreservation. Journal of Immunological Methods 125:185-189, 1989.

P-6. Chao NJ and Blume KG. Allogeneic bone marrow transplantation: Part I. Western Journal of Medicine 151:638-663, 1989.

P-7. Chao NJ and Blume KG. Autologous bone marrow transplantation: Part II. Western Journal of

Medicine 152:46-51, 1990.

P-8. Aihara M, Blume KG and Chao NJ. Assessment of purging with multidrug-resistance (MDR) modulators and etoposide (VP-16): Results of long-term marrow cultures. Experimental Hematology 18:940-944, 1990.

P-9. Chao NJ, Aihara M, Sikic BI and Blume KG. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multiply drug-resistant human leukemic cell lines and normal bone marrow. Experimental Hematology 18:1193, 1990.

P-10. Chao NJ, Rosenberg S and Horning S. CEPP(B): Well-tolerated and effective treatment for patients with Hodgkin's lymphoma. Blood 76:1293-1298, 1990.

P-11. Blume KG, Schmidt GM, Chao NJ and Forman SJ. Bone marrow transplantation from histocompatible sibling donors for patients with acute lymphoblastic leukemia. Hematology and Blood Transfusion 33:636-637, 1990.

P-12. Chao NJ, Duncan SR, Long GD, Horning SJ, Blume KG. Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplantation. Annals of Internal Medicine 114:145-146, 1991.

P-13. Aihara M, Aihara Y, Schmidt-Wolf G, Schmidt-Wolf I, Sikic BI, Blume KG and Chao NJ. A combined approach for purging multidrug resistant leukemia cell lines in bone marrow, using a monoclonal antibody and chemotherapy. Blood 77:2079-2084, 1991.

P-14. Forman SJ, Schmidt GM, Nademanee AP, Amylon MD, Chao NJ, Fahey JL, Konrad PN, Margolin KA, Niland JC, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Somlo G, Stein AS, and Blume KG. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. Journal of Clinical Oncology, 9:1570-1574, 1991.

P-15. Chao NJ, Nademanee AP, Long GD, Schmidt GM, Donlon TA, Parker P, Slovak ML, Nagasawa LS, Blume KG, and Forman SJ. Importance of bone marrow cytogenetic evaluation prior to autologous bone marrow transplantation for Hodgkin's disease. Journal of Clinical Oncology, 9:1575-1579, 1991.

P-16. Chao NJ, Forman SJ, Schmidt GM, Snyder DS, Amylon MD, Konrad PN, Nademanee AP, O'Donnell MR, Parker PM, Stein AS, Smith E, Wong RM, Hoppe RT, and Blume KG. Allogeneic bone marrow transplantation for high risk acute lymphoblastic leukemia during first complete remission. Blood, 78:1923-1927, 1991.

P-17. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P, Blume KG. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Annals of Oncology, Suppl 1:47-50, 1991.

P-18. Advani R, Chao NJ, Horning SJ, Blume KG, Ahn DK, Lamborn KR, Fleming NC, Bonnem EM, and Greenberg PL. Granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Annals of Internal Medicine, 116:183-189, 1992.

P-19. Schmidt-Wolf IGH, Aihara M, Negrin RS, Blume KG, and Chao NJ. In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. Transfusion, 32:42-45, 1992.

- P-20. Marie J-P, Brophy NA, Ehsan MN, Aihara Y, Mohamed NA, Cornbleet J, Chao NJ, and Sikic BI. Expression of Multidrug Resistance Gene *mdr1* mRNA in a Subset of Normal Bone Marrow Cells. British Journal of Hematology, 81:145-152, 1992.
- P-21. Chao NJ, Tierney DK, Bloom JR, Long GD, Barr TA, Stallbaum B, Wong RM, Negrin RS, Horning SJ, and Blume KG. Dynamic assessment of quality of life following autologous bone marrow transplantation. Blood, 80:825-830, 1992.
- P-22. Kuhl S-J, Sikic BI, Blume KG, and Chao NJ. Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. Experimental Hematology, 20:1048-1054, 1992.
- P-23. Chao NJ, Stein AS, Long GD, Negrin RS, Amylon MD, Wong RM, Forman SJ; Blume KG. Busulfan/etoposide - Initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute non-lymphoblastic leukemia. Blood, 82:319-323, 1993.
- P-24. Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L, and Blume KG. G-CSF "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery following high dose chemotherapy. Blood 81:2031-2035, 1993.
- P-25. Schlegel PG, Schmidt-Wolf G, Schmidt-Wolf IGH, Kwak L, Blume KG, and Chao NJ. LAK activity against autologous lymphoma cells following bone marrow transplantation. Cancer Research, Therapy and Control, 3:145-152, 1993.
- P-26. Schmidt GM, Niland JC, Forman SJ, Fonbuena PP, Dagens AC, Grant MM, Ferrell BR, Barr TA, Stallbaum BA, Chao NJ, and Blume KG. Extended follow-up in 212 long-term allogeneic bone marrow transplant survivors. Transplantation, 55:551-557, 1993.
- P-27. Chao NJ, Advani RA, Berry GJ, Horning SJ, Weiss LM and Blume KG. Acute lymphoproliferative malignancy following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Transplantation, 55: 1425-1428, 1993.
- P-28. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, and Forman SJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. New England Journal of Medicine, 327:1225-1230, 1993.
- P-29. Snyder DS, Taguchi J, Chao NJ, Amylon MD, Long GD, Negrin RS, Nademanee AP, O'Donnell MR, Schmidt GM, Stein AS, Parker PM, Smith EP, Konrad P, Stepan DE, Molina A, Lipsett JA, Hoppe RT, Niland JC, Dagens AC, Wong RM, Forman SJ, and Blume KG. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood, 82:2920-2928, 1993.
- P-30. Schriber JR, Negrin RS, Chao NJ, Long GD, Horning SJ, and Blume KG. The efficacy of granulocyte-colony stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. Leukemia, 7:1491-1495, 1993.
- P-31. Kuhl, J-S Duran GE, Chao NJ, and Sikic BI. Effects of the methoxymorpholino derivative of doxorubicin

and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemotherapy and Pharmacology, 33:10-16, 1993.

P-32. Chao NJ, Schriber J, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, and Blume KG. A randomized study of erythropoietin and G-CSF versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood, 83:2823-2828, 1994.

P-33. Snyder DS, Negrin RS, O'Donnell MR, Chao NJ, Amylon MD, Long GD, Nademanee AP, Stein AS, Parker PM, Smith EP, Somlo G, Margolin K, Lipsett JA, Hoppe RT, Slovak ML, Niland JC, Dagens AC, Wong RM, Forman SJ, and Blume KG. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood, 84:1672-1679, 1994.

P-34. Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C, Lucas KS, and Blume KG. Granulocyte colony stimulating factor (G-CSF) following allogeneic bone marrow transplantation. Blood, 84:1680-1684, 1994.

P-35. Schlegel PG, Schlegel PG; Aharoni R; Smilek DE; Fernandez LP; McDevitt HO; Tran N; Vaysburd M; Chao NJ. Prevention of graft-versus-host disease by synthetic peptides with high binding affinity for class II MHC molecules. Blood, 84:2802-2810, 1994.

P-36. Chao NJ, Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RW, Blashke T; Blume KG. A new preparatory regimen for autologous bone marrow transplantation for patients with Hodgkin's and Non-Hodgkin's lymphoma. Cancer, 75:1354-9, 1995.

P-37. Horning SJ, Negrin RS, Chao NJ, Long GD, Hoppe RT, and Blume KG. Fractionated total body irradiation, etoposide and cyclophosphamide and autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J. Clin Oncol, 12:2552-2558, 1995.

P-38. Negrin RS, Kusnierz-Glas CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Horning SJ, Brown BW, Blume KG, and Strober S. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood, 85:3334-3341, 1995.

P-39. Fernandez LP, and Chao NJ. Lack of effect of thalidomide on IL-2 response and production. Experimental Hematology, 23:978-85, 1995.

P-40. Long GD, Negrin RS, Hoyle CF, Kusnierz-Glaz KR, Schriber JR, Blume KG, and Chao NJ. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer, 76:860-8, 1995.

P-41. Parker PM, Chao NJ, Snyder DS, Nademanee A, O'Donnell MR, Schmidt GM, Stein AS, Smith EP, Molina A, Stepan DE, Kashyap A, Planas I, Somlo G, Margolin K, Niland JC, Zwingenberger K, Wilsman K, Blume KG, and Forman SJ. Thalidomide therapy for chronic graft-versus-host disease. Blood, 86:3604-3609, 1995.

P-42. O'Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, Amylon M, Chao NJ, Negrin RS, Schmidt GM, Slovak ML, Smith EP, Snyder DS, Stein AS, Traweek T, Blume KG, Forman SJ. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. Journal of Clinical Oncology, 13(12):2973-2979, 1995.

- P-43. Zaia JA, Schmidt GM, Chao NJ Snyder DS, Nademanee A, O'Donnell MR, Stein AS, Smith EP, Molina A, Stepan DE, Kashyap A, Planas I, Somlo G, Margolin K, Niland JC, Blume KG, and Forman SJ. Pre-emptive ganciclovir based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: Long-term follow-up. Biology of Blood and Marrow Transplantation, 1(2):88-93, 1995.
- P-44. Schlegel PG, Vaysburd M, Chen Y, Butcher E, Chao NJ. Selective inhibition of T cell costimulation mediated by VCAM-1 prevents murine graft-versus-host disease. Journal of Immunology, 155: 3856-3865, 1995.
- P-45. Pattarelli P, Jeffrey RB, Chao N. Gallbladder wall thickening is neither sensitive nor specific for hepatic venoocclusive disease following bone marrow transplantation. Ultrasound International 1:163-4, 1995
- P-46. Schlegel PG, Chao NJ. Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. Leukemia and Lymphoma 18:179-184, 1996.
- P-47. Behar E, Chao NJ, Hiraki D, Krishnaswamy S, Zehnder J, and Grumet FC. Polymorphism of adhesion molecule CD31 and its association with graft vs. host disease. New England Journal of Medicine, 334:286-291, 1996.
- P-48. Schlegel PG, Aharoni R, Chen Y, Chen J, Teitelbaum D, Arnon R, Sela M, Chao NJ. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proceedings of the National Academy of Sciences (USA), 93:5061-5066, 1996.
- P-49. Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD, Hu WW, Negrin RS, Lee Y, Blume KG, and Long GD. The influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. Journal of Clinical Oncology, 15 (1) 18-25, 1996.
- P-50. Geiler CR, Baker J, Wells S, Schlegel PG, Chao NJ. Purging mobilized peripheral blood progenitor cells with 4-hydroxyperoxy-cyclophosphamide (4-HC). Cancer Research, Therapy and Control, 5 (1) 23-27, 1996.
- P-51. Parker PM, Chao NJ, Ben-Ezra J, Slatkin N, Oppenshaw H, Niland J, Linker CA, Greffe BS, Kashyap A, Moliona A, Nademanee A, O'Donell MR, Planas I, Smith EP, Snyder DS, Stepan DE, Blume KG, and Forman SJ. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine 75 (5) 279-285, 1996.
- P-52. Chao NJ, Parker PM, Niland JC, Wong RW, Dagens A, Long GD, Nademanee A, Negrin RS, Snyder DS, Hu WW, Gould KA, Tierney DK, Zwingenberger K, Forman SJ, Blume KG. Paradoxical effect of thalidomide prophylaxis on chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2:86-92, 1996.
- P-53. Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW, Wong RM, Blume KG. Evaluation of total body irradiation and chemotherapy or chemotherapy alone plus autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation, 2:76-85, 1996.
- P-54. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG. High dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory

Hodgkin's disease: Analysis of the Stanford results and prognostic indices. Blood 89, 801-814, 1996.

P-55. Kastrissios H, Chao NJ, Blaschke TF. Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. Cancer Chemother Pharmacol 38:425-430, 1996.

P-56. Chao NJ. Mobilization of peripheral blood progenitor cells by hematopoietic growth factors. Can J Oncol 5 Suppl 1:43-46 1996.

P-57. Chen Y, Schlegel PG, Tran N, Thompson D, Zehnder J, Chao NJ. Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease. Blood, 89 (4): 1452-1459, 1997.

P-58. Lee P, Zeng D, McCaulay D, Chen YF, Geiler C, Umetsu DT, Chao N. T Helper 2-Dominant Antilymphoma Immune Response is Associated with Fatal Outcome. Blood, 90(4), 1611-1167, 1997.

P-59. Chao, N Graft-vs-host disease: The viewpoint from the donor T cell. Biology of Blood and Marrow Transplantation 3:1-10, 1997

P-60. Rizzieri DA, Chao N. Treatment of non-Hodgkin's lymphoma with high dose therapy and hematopoietic stem cell support. Current Opinion in Oncology 9:(5)420-427, 1997.

P-61. Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SF, Blume KG. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biology of Blood and Marrow Transplantation 3:324-330, 1997.

P-62. Aharoni R, Schlegel PG, Teitelbaum D, Roikhel-Karpov O, Chen Y, Arnon R, Sela M, Chao NJ. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol Lett 58:79-87, 1997.

P-63. Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol 21:988-996, 1997.

P-64. Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, LeGrand S, Peters WP, Vredenburgh JJ. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. Journal of Clinical Oncology, 16:1008-1012, 1998

P-65. Rizzieri DA, Chao NJ. Prevention and Treatments of graft-versus-host disease by pharmacologic agents. Current Opinion in Organ Transplantation 3:105-111, 1998.

P-66. Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. Journal of Clinical Oncology, 17(10):3064-3074, 1999.

P-67. Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume

- KG. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Clinical Cancer Research, 5(11):3411-3418, 1999.
- P-68. Nieto Y, Cognoni PJ, Shpall EJ, Xu X, Murphy J, Vredenburgh J, Chao NJ, Bearman SI, Jones RB. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clinical Cancer Research, 5(11):3425-3431, 1999.
- P-69. Maureen R, Schmidt GM, Niland JC, Amylon MD, Dagens AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Forman SF, Blume KG, Chao NJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs-host disease: effect on chronic graft-vs-host disease and long-term survival. Biology of Blood and Marrow Transplantation, 5:285-291, 1999.
- P-70. Ferrara JLM, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biology of Blood and Marrow Transplantation, 5:347-356, 1999.
- P-71. Chen Y, Zeng D, Schlegel PG, Fedler J, Chao NJ. PG27, An Extract of *Tripterygium Wilfordii* Hook F., Induces Antigen Specific Tolerance in Bone Marrow Transplantation in Mice. Blood, 95:705-710, 1999.
- P-72. Bhalla KS, Wilczynski SW, Abushamaa AM, Petros WP, McDonald CS, Loftis JS, Chao NJ, Vredenburgh JJ, Folz RJ. Pulmonary Toxicity of Induction Chemotherapy Prior to Standard or High-dose chemotherapy with Autologous Hematopoietic Support. Am J Respir Crit Care Med, 161:17-25, 2000.
- P-73. Shbarou RM, Chao NJ, Morgenlander JC. Cyclosporin A-Related Cerebral Vasculopathy. Bone Marrow Transplantation, Bone Marrow Transplant 7:801-4, 2000.
- P-74. Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NJ, Hu WW, Johnston LF, Long GD, Strober S, Wong RM, Feiner RH, Kobler S, Negrin RS. Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant. 6:506-512, 2000.
- P-75. Brodwater BK, Silber JS, Smith TP, Chao NJ, Suhocki PV, Ryan JM, Newman GE. Conversion of indwelling chest port catheters to tunneled central venous catheters. J Vasc Interv Radiol. 9:1137-1142, 2000.
- P-76. Chen BJ, Liu C, Cui X, Fidler JM, Chao NJ. Prevention of graft-vs-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T-cell expansion. Transplantation, 70:1442-1447, 2000.
- P-77. Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, Amylon MD, Tierney DK, O'Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Blume KG. Equivalence of two effective GVHD prophylaxis regimens: results of a prospective blinded randomized trial. Biol Blood Marrow Transplant, 6:254-261, 2000.
- P-78. Chen BJ, Morris RE, Chao NJ. Graft-versus-Host disease prevention by rapamycin: cellular mechanisms. Biol Blood Marrow Transplant, 6:529-536, 2000.
- P-79. Rizzieri DA, Chao NJ. Immunosuppressive Drug Therapy for Graft Versus Host Disease Prophylaxis in

Patients Undergoing Bone Marrow or Peripheral Blood Stem Cell Transplantation. Graft, 3:235-237, 2000.

P-80. Chen Y, Zeng D, Schlegel PG, Fidler J, Chao NJ. PG27, an extract of *Tripterygium wilfordii hook f*, induces antigen-specific tolerance in bone marrow transplantation in mice. Transplantation, 95:705-710, 2000.

P-81. Hu WW, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Wong RM, Chao NJ, Long GD, Feiner RH and Blume KG. Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer. No improvement in outcomes compared with single-course high-dose therapy. Biol Blood Marrow Transplant, 6:58-69, 2000.

P-82. Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma Biol Blood Marrow Transplant;6:352-358, 2000

P-83. Chao NJ. Progress in graft-versus-host disease. J Hematother Stem Cell Res. 9:295-296, 2000

P-84. Kurtzberg J, Martin P, Chao NJ Stevens C, Rubinstein P. Unrelated placental blood in marrow transplantation. Stem Cells,18:153-154, 2000

P-85. Chen BJ, Morris RE, Chao NJ. Graft-versus-host disease prevention by rapamycin: Cellular mechanisms. Transplantation, 6:529-36, 2000.

P-86. Chen BJ, Chen Y, Cui X, Fidler JM, Chao NJ. Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion. Transplantation, 70: 1442-1447, 2000.

P-87. Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, Brown BW, Blume KG. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood, Jan 15;97(2):404-409 2001.

P-88. Brodwater BK. Silber JS. Smith TP. Chao NJ. Suhocki PV. Ryan JM. Newman GE. Conversion of indwelling chest port catheters to tunneled central venous catheters. Journal of Vascular & Interventional Radiology. 11(9):1137-42, 2000

P-89. Ziske C, Märten A, Schöttker B, Buttgerit P, Schakowski F, Gorschlüter M, von Rücker A, Scheffold C, Chao NJ, Sauerbruch T, Schmidt-Wolf IGH. Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. Molecular Therapy, 3(1):54-60, 2001.

P-90. Gocker H, Haznedaroglu I, Chao NJ. Acute graft-versus-host disease: Pathogenesis and management. Experimental Hematology, 29(3):259-77, 2001.

P-91. Boeckh M, Bowden RA, Storer B, Chao NJ, Speilberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, and Zaia JA. Randomized, Placebo-Controlled, Double-Blind Study of a Cytomegalovirus-Specific Monoclonal Antibody (MSL-109) for Prevention of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 7(6)343-351, 2001.

P-92 Klein A, Patel DD, Gooding ME, Sempowski GD, Chen BJ, Kurtzberg J, Haynes BF, Chao NJ. Central

Versus Peripheral Mechanisms of T-cell Recovery in Adults and Children Following Umbilical Cord Blood Transplant Biology of Blood and Marrow Transplant, 7:454-466, 2001.

P-93. Stuart MF, Chao NJ, Horning SF, Wong RM, Negrin RS, Johnston LF, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE. Efficacy and Toxicity of a CCNU-Containing High-Dose Chemotherapy Regimen followed by Autologous Hematopoietic Cell Transplantation in Relapsed or Refractory Hodgkin's Disease. Biology of Blood & Marrow Transplantation, 7:552-560, 2001.

P-94. McGaughey DS, Nikcevich DA, Long GD, Vredenburgh JJ, Rizzieri D, Smith CA, Broadwater G, Loftis JS, McDonald C, Morris AK, Folz FD, Chao NJ. Inhaled Steroids as Prophylaxis for Delayed Pulmonary Toxicity Syndrome in Breast Cancer Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation. Biology of Blood & Marrow Transplantation, 7:274-278, 2001.

P-95. Rizzieri DA, Long GD, Gasparetto C, Vredenburgh JJ, Morris A, Davis P, Chao NJ Successful allogeneic engraftment of mismatched unrelated cord blood following a non myeloablative preparative regimen. Blood, 98:3486-3488, 2001.

P-96. Chen BJ, Cui X, Sempowski GD, Gooding ME, Liu C, Haynes B, Chao NJ. A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution. Blood 99: 364-371, 2002.

P-97. Chen BJ, Cui X, Chao NJ. Addition of a second different allogeneic graft accelerates white cell and platelet engraftment after T cell-depleted bone marrow transplantation. Blood 99: 2235-2240, 2002.

P-98. Chen BJ, Cui X, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood, 99:3083-8, 2002.

P-99. Chen BJ, Chao NJ. Immunosuppressive and Anti-Inflammatory Effects of Triptolide. Drugs of the Future, 27:57-60, 2002

P-100. Chao NJ, Cong XL, Rooney B, Chen BJ, Long GD, Vredenburgh JJ, Morris A, Gasparetto C, Rizzieri DA. Non-Myeloblastic regimen preserves "Niches" allowing for peripheral expansion of donor T-cells. Biology of Blood and Marrow Transplantation, 8:249-256, 2002.

P-101. Morse MA, Rizzieri D, Stenzel T, Hobeika AC, Vredenburgh J, Chao NJ, Clay TM, Mosca PJ, Lyerly HK. Dendritic cell recovery following non-myeloablative allogeneic stem cell transplants. Journal of Hematotherapy and Stem Cell Research, 11(4):659-68, 2002.

P-102. Gasparetto C. Morse M. Rooney B. Vredenburgh JJ. Long GD. Rizzieri DA. Loftis J. Chao NJ. Smith C. Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF. Cytokine. 18(1):8-19, 2002.

P-103. McCune SL. Gockerman JP. Moore JO. Decastro CM. Bass AJ. Chao NJ. Long GD. Vredenburgh JJ. Gasparetto C. Adams D. Payne N. Rizzieri DA. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leukemia & Lymphoma 43(5):1007-11, 2002

- P-104. Stuart MJ, Peters WP, Broadwater G, Hussein A, Ross M, Marks LB, Folz RJ, Long GD, Rizzieri D, Chao NJ, Vredenburgh JJ. High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. Biol Blood Marrow Transplant. 8:666-73, 2002
- P-105. Rizzieri DA. Ibom VK. Moore JO. DeCastro CM. Rosner GL. Adams DJ. Foster T. Payne N. Thompson M. Vredenburgh JJ. Gasparetto C. Long GD. Chao NJ. Gockerman JP. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clinical Cancer Research. 9(2):663-8, 2003
- P-106. Long GD, Laughlin M, Madan B, Kurtzberg J, Rubinstein P, Gasparetto C, Morris A, Rizzieri DA, Smith C, Vredenburgh JJ, Halperin EC, Broadwater G, Niedzwiecki D, Chao NJ. Unrelated cord blood transplantation in adult patients. Biol of Blood and Marrow Transplant, 9:772-80, 2003
- P-107. Benny J. Chen, M.D.,M.S., Xiuyu Cui, M.S., Gregory D. Sempowski, Ph.D, and Nelson J. Chao, M.D. Growth Hormone Accelerates Immune Recovery Following Allogeneic T Cell-Depleted Bone Marrow Transplantation in Mice. Exp. Hematol, 31:953-8, 2003
- P-108. Rizzieri DA. Talbot JT. Long GD. Vredenburgh JJ. Gasparetto C. Smith CS. Colvin MO. Adams D. Morris A. Dodge R. Loftis J. Waters-Pick B. Reese M. Carawan H. Koh LP. Chao NJ. 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. Biology of Blood & Marrow Transplantation. 9(3):183-8, 2003
- P-109. Jaroscak J. Goltry K. Smith A. Waters-Pick B. Martin PL. Driscoll TA. Howrey R. Chao N. Douville J. Burhop S. Fu P. Kurtzberg J. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood. 101(12):5061-7, 2003
- P-110. Goggins TF, Chao N. Depletion of host reactive T cells by photodynamic cell purging and prevention of graft versus host disease. Leuk Lymphoma. 44:1871-9, 2003.
- P-111. Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N. New developments in allotransplant immunology. Hematology (Am Soc Hematol Educ Program). 350-71, 2003.
- P-112. Benny J. Chen, Xiuyu Cui, Gregory D. Sempowski, Congxiao Liu, and Nelson J. Chao Transfer of Allogeneic CD62L⁻ Memory T Cells without Graft-vs.-Host Disease. Blood, 103:1534-1541, 2004
- P-113. Liang-Piu Koh, M.D.Nelson J. Chao, M.D. Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. Biol Blood and Marrow Transplant, 10(1):1-22, 2004
- P-114. Carole B Miller, MD, Edmund K Waller, MD, PhD, Hans G Klingemann, MD, PhD, MC Dignani, MD, Elias J Anaissie, MD, Pablo J Cagnoni, MD, Peter McSweeney, MD, Penny R Fleck, Steven M Fruchtman, MD, Joseph McGuirk, MD, Nelson J Chao, MD. Lipid Formulations of Amphotericin B Preserve and Stabilize Renal Function in HSCT Recipients. Bone Marrow Transplant, 33, 543 - 548 2004
- P-115. Nelson J. Chao. Minors Come of Age (Minor Histocompatibility Antigens and Graft-versus-Host Disease). Biol Blood and Marrow Transplant 10: 215-223, 2004

P-116. Nieto Y, Vredenburgh JJ, Shpall EJ, Bearman SI, McSweeney PA, Chao N, Rizzieri D, Gasparetto C, Matthes S, Baron AE, Jones RB. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clin Cancer Res 10:7136-43, 2004.

P-117. Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, Toaso B, Anderson E, Lagoo A, Clayton S, Pegram CN, Moore JO, Gockerman JP, DeCastro C, Gasparetto C, Chao NJ, Bigner DD. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 104:642-8, 2004

P-118. Benny J. Chen, Xiuyu Cui, Gregory D. Sempowski, Jos Domen, and Nelson J. Chao Hematopoietic Stem Cell Dose Correlates with the Speed of Immune Reconstitution after Stem Cell Transplantation. Blood 103: 4344-4352, 2004

P-119. Bhagat, R, Rizzieri DA, Vredenburgh JJ, Chao NJ, Folz RJ. Pulmonary Sarcoidosis Following Stem Cell Transplantation. Chest 126: 1-4, 2004

P-120. Snyder MJ, Stenzel TT, Buckley PJ, Lagoo AS, Rizzieri DA, Gasparetto C, Vredenburgh JJ, Chao N, Gong JZ. Post-transplant lymphoproliferative disorder following non-myeloablative allogenic stem cell transplantation. Am J Surg Pathol 28:794-800, 2004.

P-121. Rizzieri DA. Sand GJ. McGaughey D. Moore JO. DeCastro C. Chao NJ. Vredenburgh JJ. Gasparetto C. Long GD. Anderson E. Foster T. Toaso B. Adams D. Niedzwiecki D. Gockerman JP. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer. 100(11):2408-14, 2004

P-122. Chao N. Hematopoietic stem cell transplantation. Curr Opin Hematol 11:373-4, 2004.

P-123. Giles FJ. Rodriguez R. Weisdorf D. Wingard JR. Martin PJ. Fleming TR. Goldberg SL. Anaissie EJ. Bolwell BJ. Chao NJ. Shea TC. Brunvand MM. Vaughan W. Petersen F. Schubert M. Lazarus HM. Maziarz RT. Silverman M. Beveridge RA. Redman R. Pulliam JG. Devitt-Risse P. Fuchs HJ. Hurd DD. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Research. 28(6):559-65, 2004

P-124. Chao NJ, Koh L-P, Long GD, Gasparetto C, Horwitz M, Morris A, Lassiter M, Sullivan KM and Rizzieri DA. Adult Recipients of Umbilical Cord Blood Transplantation Following Non-myeloablative Preparative Regimen. Biol Blood and Marrow Transplant 10: 569-575, 2004.

P-125. Chao NJ, Emerson SG, Weinberg KI. Stem cell transplantation (cord blood transplants). Hematology (Am Soc Hematol Educ Program). 354-71, 2004.

P-126. Hiemenz J, Cagnoni P, Simpson D, Devine S, Chao N, Keirns J, Lau W, Facklam D, Buell D. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother. 49:1331-6, 2005.

P-127. Cornetta K, Laughlin M, Carter S, Wall D, Weinthal J, Delaney C, Wagner J, Sweetman R, McCarthy P, Chao N. Umbilical cord blood transplantation in adults: Results of the prospective cord blood transplantation (COBLT). Biol Blood and Marrow Transplant. 11:149 -160, 2005.

- P-128. Johnston LA, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease Biol Blood and Marrow Transplantation 11: 47-55, 2005
- P-129. Wanko SO and Chao NJ. Non-pharmacological approaches to graft versus host prevention. Blood Reviews, 19:203-211, 2005.
- P-130. Arcasoy MO, Chao NJ. T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. Am J Hematol 78:161-3, 2005.
- P-131. Storms RW, Green PD, Safford KM, Niedzwiecki D, Cogle CR, Colvin OM, Chao NJ, Rice HE, Smith CA. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood 106:95-102, 2005.
- P-132. Le NT, Chen BJ, Chao NJ. Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting. Cytotherapy. 7:126-33, 2005.
- P-133. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman C, Yancey D, Phan A, Chao NJ, Gilboa E, and Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after *in vivo* depletion of regulatory T cells. J Clin Invest., 115:3623-33, 2005.
- P-134. Congxiao Liu C, He M, Rooney , Kepler TB, and Chao NJ. Longitudinal Analysis of T-Cell BV Receptor Repertoire in Patients with Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. Biol Blood and Marrow Transplant, Biol of Blood and Marrow Transplant. 12:335-45, 2006.
- P-135. Chao NJ and Chen BJ. Prophylaxis and Treatment of Acute GVHD. Seminars in Hematology, 43:23-41, 2006
- P-136. Chute JP, Muramoto GG, Dressman HK, Wolfe G, Chao NJ, Lin S. Molecular profile and partial functional analysis of novel endothelial cell derived growth factors that regulate hematopoiesis. Stem Cells 24:1315-1327, 2006
- P-137. Muramoto G, Chen B, Cui X, Chao N, Chute J. Vascular endothelial cells produce soluble factors capable of rescuing human hematopoietic stem cells following radiation injury. Biol of Blood and Marrow Transplant. 2006; 12:530-540.
- P-138. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, and McDonnell DP. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Nat Acad Sci 2006; 109: 11707-11712.
- P-139. Wanko, SO, Broadwater G, Folz RJ, Chao, NJ. Diffuse Alveolar Hemorrhage: Retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. Biol of Blood and Marrow Transplant 12:949-953, 2006
- P-140. Weisdorf D , Chao N, Waselenko J, Dainiak N, Armitage J, McNiece I, Confer D. Acute Radiation Injury: Contingency Planning for Triage, Supportive Care, and Transplantation. Biol Blood and Marrow Transplant 2006; 6; 672 - 682.

- P-141. Alexander BD, Dodds A, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic cell transplantation. *Transplant Infectious Disease* 2006; 8:13-20.
- P-142. Lagoo AS, Gong JZ, Stenzel TT, Goodman BK, Buckley PJ, Chao NJ, Gasparetto C, Long GD, Rizzieri DA. Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment. *Arch Pathol Lab Med.* 2006 Oct;130(10):1479-88
- P-143. Wanko SO, Broadwater G, Folz RJ, Chao NJ. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. *Biol Blood Marrow Transplant.* 2006 Sep;12(9):949-53.
- P-144. Le NT and Chao N. Regulating regulatory T cells. *Bone Marrow Transplantation* 2007; 39:1-9.
- P-145. Chen BJ, Deoliveira D, Cui X, Le NT, Son J, Whitesides JF, and Chao NJ. Inability of memory T cells to induce GVHD is a result of an abortive alloresponse. *Blood* 2007; 109:3115-3123.
- P-146. Chao NJ. Accidental or intentional exposure to ionizing radiation: Biodosimetry and treatment options. *Exp Heme* 2007; 35:24-27
- P-147. Chute JP, Muramoto GG, Rickman D, Himburg H, Chen B, and Chao NJ. Transplantation of vascular endothelial cells mediates the hematopoietic recovery and survival of lethally irradiated mice. *Blood*, 2007; 109:2365-2372.
- P-148. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Lu C, Marshall D, Vredenburgh JJ, Gockerman J, Decastro C, Moore J, Chao NJ. Partially matched, non-myeloablative allogeneic transplantation: Clinical Outcomes and Immune Reconstitution. *J Clin Oncol*, 2007; 25: 690-697.
- P-149. Dressman HK, Muramoto GG, Chao NJ, Meadows S, Marshall D, Ginsburg GC, Nevins JR, Chute JP. Gene Expression Signatures That Predict Radiation Exposure in Mice and Humans. *PLoS Med* 2007; 4(4): e106
- P-150. Weisdorf D, Apperley J, Courmelon P, Gorin N, Wingard J, Chao N. Radiation Emergencies: Evaluation, Management, and Transplantation. *Biol Blood and Marrow Transplant* 2007;13:103 – 106.
- P-151 Horwitz M, Spasojevic I, Morris A, Telen M, Essell J, Gasparetto C, Sullivan K, Long G, Chute J, Chao N. Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics. *Biol Blood and Marrow Transplant*, 2007;13:1422 – 1426.
- P-152. Chao NJ. Are there effective new strategies for the treatment of acute and chronic GVHD? *Best Practice and Research Clinical Hematology* 2008; 21:93-98.
- P-153. Meadows SK, Dressman HK, Muramoto GG, Himburg H, Salter A, Wei ZZ, Ginsburg G, Chao NJ, Nevins JR, and Chute J. Gene Expression Signatures of Radiation Response Are Specific, Durable and Accurate in Mice and Humans. *PLoS ONE.* 2008; 3(4): e1912.

- P-154. Koh L-P and Chao NJ. Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: A review. *Blood Cells, Molecules, and Diseases* 2008; 40: 20-24
- P-155. Drew J, Winston, Jo-Anne H, Young, Vinod Pullarkat, Genovefa A, Papanicolaou, Ravi Vij, Estil Vance, George J, Alangaden, Roy F, Chemaly, Finn Petersen, Nelson Chao, Jared Klein, Kellie Sprague, Stephen A, Villano, and Michael Boeckh. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. *Blood* 2008;111:5403-5410
- P-156. Weinstock DM, Case C Jr, Bader JL, Chao NJ, Coleman CN, Hatchett RJ, Weisdorf DJ, Confer DL. Radiologic and nuclear events: contingency planning for hematologists/oncologists. *Blood*. 2008 Jun 15;111(12):5440-5. Epub 2008 Feb 20.
- P-157. Chao N. Memory T cells. *Biol Blood Marrow Transplant*. 2008 Jan;14(1 Suppl 1):17-9.
- P-158. Byrne BJ, Horwitz M, Long GD, Gasparetto C, Sullivan KM, Chute J, Chao NJ, Rizzieri DA. Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. *Bone Marrow Transplant*. 2008 Jan;41(1):39-43.
- P-159. Koh LP, Rizzieri DA, Chao NJ. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. *Biol Blood Marrow Transplant*. 2007 Nov;13(11):1249-67.
- P-160. Flidner TM, Chao NJ, Bader JL, Boettger A, Case C Jr, Chute J, Confer DL, Ganser A, Gorin N-C, Gourmelon P, Graessle DH, Krawisz R, Meineke V, Niederwieser D, Port M, Powles R, Sirohi B, Weinstock DM, Wiley A, Coleman CN. Stem Cells, Multi-organ Failure in Radiation Emergency Medical Preparedness: A US/European Consultation Workshop. *Stem Cells* 1066-5099/2009/\$30.00/0 doi: 10.1002/stem.16
- P-161. Doan PL, Chao NJ. The role of oral beclomethasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease. *Drugs*. 2009 Jul 9;69(10):1339-50. doi: 10.2165/00003495-200969100-00004.
- P-162. Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. *Biol Blood Marrow Transplant*. 2009 Jul;15(7):777-84. Epub 2009 May 13.
- P-163. Rizzieri DA, O'Brien JA, Broadwater G, Decastro CM, Dev P, Diehl L, Beaven A, Lagoo A, Gockerman JP, Chao NJ, Moore JO. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. *Cancer*. 2009 Jul 1;115(13):2922-9.
- P-164. Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao N, Gockerman JP, Garcia RA, Rizzieri DA. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. *Leuk Lymphoma*. 2009 May;50(5):741-8.
- P-165. Osada T, Woo CY, McKinney M, Yang XY, Lei G, Labreche HG, Hartman ZC, Niedzwiecki D, Chao N, Amalfitano A, Morse MA, Lysterly HK, Clay TM. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. *Clin Cancer Res*. 2009 Apr 15;15(8):2789-96. Epub 2009 Apr 7.

- P-166. Horkheimer I, Quigley M, Zhu J, Huang X, Chao NJ, Yang Y. Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation. *Blood*. 2009 May 21;113(21):5330-9. Epub 2009 Mar 11.
- P-167. Salter B, Meadows SK, Muramoto GG, Himburg H, Doan P, Daher P, Russell L, Chen B, Chao NJ, Chute JP. Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo. *Blood*. 2009 Feb 26;113(9):2104-7. Epub 2009 Jan 13.
- P-168. Safi R, Muramoto GG, Salter AB, Meadows S, Himburg H, Russell L, Daher P, Doan P, Leibowitz MD, Chao NJ, McDonnell DP, Chute JP. Pharmacological manipulation of the RAR/RXR signaling pathway maintains the repopulating capacity of hematopoietic stem cells in culture. *Mol Endocrinol*. 2009 Feb;23(2):188-201. Epub 2008 Dec 23.
- P-169. Chao N. What do you do with the "pink sheets?". *Hematology Am Soc Hematol Educ Program*. 2008:23-5.
- P-170. Rizzieri DA, Dev P, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Chao NJ. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. *Bone Marrow Transplant*. 2009 Feb;43(4):327-33. Epub 2008 Oct 13.
- P-171. Kang Y, Chao NJ, Aversa F. Unmanipulated or CD34 selected haplotype mismatched transplants. *Curr Opin Hematol*. 2008 Nov;15(6):561-7. Review.
- P-172. Koh LP, Chao N. Haploidentical hematopoietic cell transplantation. *Bone Marrow Transplant*. 2008 Aug;42 Suppl 1:S60-S63. Review.
- P-173. Hobeika A, Osada T, Serra D, Peplinski S, Hanson K, Tanaka Y, Niedzwiecki D, Chao N, Rizzieri D, Lyerly H, Clay T, Morse M. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. *Cytotherapy*. 2008;10(3):289-302.
- P-174. Horwitz ME, Morris A, Gasparetto C, Sullivan K, Long G, Chute J, Rizzieri D, McPherson J, Chao N. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. *Biol Blood Marrow Transplant*. 2008 May;14(5):591-4.
- P-175. Kang Y, Chen B, DeOliveira D, Mito J and Chao NJ. AMD3100, a CXCR4 antagonist, selectively enhances donor hematopoietic cell engraftment. *Plos One* 2010;5(6):e11316.
- P-176. Chen BJ, Deoliveira D, Spasojevic I, Sempowski GD, Jiang C, Owzar K, Wang X, Gesty-Palmer D, Cline MJ, Bourlonds JD, Dugan G, Meadows SK, Daher P, Muramoto G, Chute JP, and Chao NJ. Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and non human primates. *Plos One*, 2010; 5(6): e11056. doi:10.1371/journal.pone.0011056
- P-177. Himburg H, Meadows SK, Muramoto GG, Salter A, Chao NJ, Nevins JR, and Chute J. Pleiotrophin, a novel molecule supporting hematopoietic re generation. *Nature Medicine*, 16, 475-482 (21 March 2010) doi:10.1038/nm.2119.

P-178. Horwitz M and Chao NJ. Non myeloablative umbilical cord transplantation. *Best Practice and Research Clinical Hematology* 2010; 23

P-179. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang M-J, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. *Lancet Oncology* 2010; 11:653-660

P-180. Rizzieri DA, Storms R, Chen D-F, Long G, Yang Y, Nikcevich DA, Gasparetto C, Horwitz M, Chute J, Sullivan K, Hennig T, Misra D, Apple C, Baker M, Morris A, Green PG, Hasselblad V and Chao NJ. Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation. *Biol Blood and Marrow Transplant* 2010; 16; 11107-1114.

P-181. Cristina Gasparetto, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, John P. Chute, Keith M. Sullivan, George Keogh, Rachel Neuwirth, Patricia H. Davis RN, Linda M. Sutton, Russell D. Anderson, Nelson J. Chao, and David Rizzieri. Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma. *Biol Blood Marrow Transplant*. 2010 Jan;16(1):70-7.

P-182. Christopher A. Crout, Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos DeCastro, Gwynn D. Long, Louis Diehl, Christina Gasparetto, Donna Niedzwiecki, Jon Edwards, Leonard Prosnitz, Mitchell Horwitz, Jon Chute, Ashley Morris, Patricia Davis, Anne Beaven, Nelson J. Chao, Francis Ali-Osman, David A. Rizzieri. Overcoming Drug Resistance in Mantle Cell Lymphoma Using a Combination of Dose Dense and Intense Therapy. *Cancer Invest*. 2010 28:654-60.

P-183. J. Palmer, T. Goggins, G. Broadwater, N.Chao, G. Long, M. Horwitz, A. Beavens, J. Chute, K. Sullivan, C. Gasparetto, E. Coleman, D. Rizzieri. Early Pre/Post Transplant Fluoro-Deoxyglucose Positive Emission Tomography (FDG-PET) does predict outcome for patients undergoing hematopoietic stem cell transplantation in non-Hodgkins and Hodgkins lymphoma. *Biol Blood and Marrow Transplantation* 46; 847-851, 2010.

P-184. David A. Rizzieri, Robert Storms, Dong-Feng Chen, Gwynn Long, Daniel A. Nikcevich, Cristina Gasparetto, Mitchell Horwitz, John Chute, Keith Sullivan, Therese Hennig, Debashish Misra, Christine Apple, Megan Baker, Ashley Morris, Patrick G. Green, Vic Hasselblad, Nelson J. Chao. Natural Killer Cell Enriched Donor Lymphocyte Infusions From A 3-6/6 HLA Matched Family Member Following Non-Myeloablative Allogeneic Stem Cell Transplantation. *Biol Blood and Marrow Trns* 2010. 8:1107-1114.

P-185. Kanda J, Chao NJ, Rizzieri DA. Haploidentical transplantation for leukemia. *Curr Oncol Rep*. 2010 Sep;12(5):292-301

P-186. Craciunescu OI, Steffey BA, Kelsey CR, Larrier NA, Paarz-Largay CJ, Prosnitz RG, Chao N, Chute J, Gasparetto C, Horwitz M, Long G, Rizzieri D, Sullivan KM. Renal Shielding and Dosimetry for Patients with Severe Systemic Sclerosis Receiving Immunoablation with Total Body Irradiation in the Scleroderma: Cyclophosphamide or Transplantation Trial. *Int J Radiat Oncol Biol Phys*. 2010 Aug 26. [Epub ahead of print]

P-187. Muramoto G, Russell JL, Safi R, Salter A, Himburg H, Daher P, Meadows S, Doan P, Storms R, Chao N, McDonnell D, Chute JP. Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity. *Stem Cells* 28:523-534, 2010

- P-188. Davids M, Case C, Hornung R, Chao N, Chute JP, Coleman N, Weisdorf D, Confer D, Weinstock D. Assessing surge capacity for radiation victims with marrow toxicity. *Biol Blood Marrow Transplant* Apr 2010 Epub ahead of print
- P-189. Meadows SK, Dressman H, Daher P, Himburg H, Russell JL, Doan P, Chao NJ, Lucas J, Nevins J, Chute JP. Diagnosis of partial body radiation exposure in mice using peripheral blood gene expression profiles. *PLoS ONE* 5(7): e11535, 2010
- P-190. Liu C, Chen BJ, DeOliveira D, Sempowski GD, Chao NJ and Storms RW. Progenitor cell dose determines the pace and completeness of engraftment in a xenograft model for cord blood transplantation. *Blood* 116; 5518-5527, 2010.
- P-191. Kelsey CR, Horwitz ME, Chino JP, Craciunescu O, Steffey B, Folz RJ, Chao NJ, Rizzieri DA, Marks LB. Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: An Assessment of Risk Factors. *Int J Radiat Oncol Biol Phys.* 2010 Oct 5. [Epub ahead of print]
- P-192. Palmer JM, Chen BJ, DeOliveira D, Le ND, Chao NJ. Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells. *Bone Marrow Transplant.* 2010 Feb;45(2):379-84. Epub 2009 Jul 13.
- P-193. Doan PL, Chao NJ. Advances in cord blood transplants in adults. *F1000 Med Rep.* 2010 Feb 11;2. pii: 12.
- P-194. Nicholas Dainiak, MD, FACP, Robert Nicolas Gent, MB, ChB, FFPH, Zhanat Carr, MD, PhD, Rita Schneider, MD, Judith Bader, MD, Elena Buglova, MD, PhD, DrSci, Nelson Chao, MD, MBA, C. Norman Coleman, MD, Arnold Ganser, MD, Claude Gorin, MD, Martin Hauer-Jensen, MD, PhD, FACS, L. Andrew Huff, MD, Patricia Lillis-Hearne, MD, Kazuhiko Maekawa, MD, PhD, Jeffrey Nemhauser, MD, Ray Powles, CBE, MD, BSc, FRCP, FRCPath, Holger Schünemann, MD, PhD, Alla Shapiro, MD, PhD, Leif Stenke, MD, PhD, Nelson Valverde, MD, David Weinstock, MD, Douglas White, MD, MAS, Joseph Albanese, PhD and Viktor Meineke, MD. First Global Consensus for Evidence-Based Management of the Hematopoietic Syndrome Resulting From Exposure to Ionizing Radiation. *Disaster Medicine and Public Health Preparedness* 2011;5:202. Horwitz M and Chao NJ. Umbilical cord transplantation for treatment of non-malignant disorders. *Cellular Therapy and Transplantation* 2010: 2; e.000069.01
- P-195. David A. Rizzieri, Christopher Crout, Robert Storms, Jared Golob, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, Mitchell Horwitz, John Chute, Anand S. Lagoo, Ashley Morris, Anne Beaven, Yiping Yang, Bercedis Peterson, Zhiguo Li and Nelson J. Chao. Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors. *Cancer Investigation* 29; 56-61, 2011
- P-196. Andrea L. DiCarlo, Carmen Maher, John L. Hick, Dan Hanfling, Nicholas Dainiak, Nelson Chao, Judith L. Bader, C. Norman Coleman, and David M. Weinstock. Radiation Injury after a Nuclear Detonation: Medical Consequences and the Need for Scarce Resources Allocation. *Disaster Medicine and Public Health Preparedness* 5; S32-S44, 2011.
- P-197. Ross JR, Case C, Confer D, Weisdorf DJ, Weinstock D, Krawisz R, Chute J, Wilhauk J, Navarro W, Hartzman R, Coleman CN, Hatchett R, Chao N. Radiation Injury Treatment Network (RITN): Healthcare Professionals Preparing for a Mass Casualty Radiological or Nuclear Incident. *Int J Rad Biol* epub 2011
- P-198. Kanda J, Rizzieri DA, Gasparetto C, Long GD, Chute JP, Sullivan KM, Morris A, Smith CA, Hogge

DE, Nitta J, Song K, Niedzwiecki D, Chao NJ, Horwitz ME. Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning. *Biol Blood Marrow Transplant*. 2011 Jun;17(6):867-74. Epub 2010 Sep 22.

P-199. Zhang P, Chen BJ, Chao NJ. Prevention of GVHD without losing GVL effect: windows of opportunity. *Immunol Res*. 2011 49:49-55.

P-200. Deoliveira D, Jiao Y, Ross JR, Corbin K, Xiao Q, Toncheva G, Anderson-Evans C, Yoshizumi TT, Chen BJ, Chao NJ. An ear punch model for studying the effect of radiation on wound healing. *Int J Radiat Biol*. 2011; 87;8:869-877

P-201. Weisdorf D, Weinstock D, Case C, Chao N, Confer DL. Planning and Response to Radiation Exposures. *Biol Blood Marrow Transplant*. 2011 Jun 15

P-202. Klymenko SY, Belyi DA, Ross JR, Owzar K, Jiang C, Li Z, Minchenko JN, Kovalenko AN, Bebesko VG, Chao NJ. Hematopoietic cell infusion for the treatment of nuclear disaster victims: New data from the Chernobyl accident. *Int J Radiat Biol* 2011;87:846-850

P-203. M E Horwitz, J P Chute, C Gasparetto, G D Long, C McDonald, A Morris, D A Rizzieri, K M Sullivan and N J Chao. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. *Bone Marrow Transplant* 2011; 1-5

P-204. Oana I. Craciunescu, Beverly A. Steffey, Chris R. Kelsey, Nicole A. Larrier, Cathy J. Paarz-Largay, Robert G. Prosnitz, Nelson Chao, John Chute, Cristina Gasparetto, Mitchell Horwitz, Gwynn Long, David Rizzieri, Keith M. Sullivan. Renal Shielding and Dosimetry for Patients With Severe Systemic Sclerosis Receiving Immunoablation With Total Body Irradiation in the Scleroderma: Cyclophosphamide or Transplantation Trial. *Int J Rad Onc Biol Phys* 2011;79:1248-1255

P-205. Kanda, Junya; Kawabata, Hiroshi; Chao, Nelson J. Iron overload and allogeneic hematopoietic stem-cell transplantation. *Exp Rev Hematol* 2011; 4:71-80

P-206. Nicholas Dainiak, Robert Nicolas Gent, Zhanat Carr, Rita Schneider, Judith Bader, Elena Buglova, Nelson Chao, C. Norman Coleman, Arnold Ganser, Claude Gorin, Martin Hauer-Jensen, L. Andrew Huff, Patricia Lillis-Hearne, Kazuhiko Maekawa, Jeffrey Nemhauser, Ray Powles, Holger Schünemann, Alla Shapiro, Leif Stenke, Nelson Valverde, David Weinstock, Douglas White, Joseph Albanese, Viktor Meineke, Literature Review and Global Consensus on Management of Acute Radiation Syndrome Affecting Nonhematopoietic Organ Systems. *Dis Med Public Health Preparedness* doi: 10.1001/dmp.2011.73

P-207. J Kanda, M E Horwitz, G D Long, C Gasparetto, K M Sullivan, J P Chute, A Morris, T Hennig, Z Li, N J Chao and D A Rizzieri. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant* 2011; 1-6

P-208. D-F Chen, V K Prasad, G Broadwater, N L Reinsmoen, A DeOliveira, A Clark, K M Sullivan, J P Chute, M E Horwitz, C Gasparetto, G D Long, Y Yang, N J Chao, D A Rizzieri. Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. *Bone Marrow Transplant* 2011; 1-7

P209. Madan Jagasia, Mukta Arora, Mary E. D. Flowers, Nelson J. Chao, Philip L. McCarthy, Corey S. Cutler, Alvaro Urbano-Ispizua, Steven Z. Pavletic, Michael D. Haagenson, Mei-Jie Zhang, Joseph H. Antin, Brian J. Bolwell, Christopher Bredeson, Jean-Yves Cahn, Mitchell Cairo, Robert Peter Gale, Vikas Gupta, Stephanie J. Lee, Mark Litzow, Daniel J. Weisdorf, Mary M. Horowitz, MD, Theresa Hahn. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. *Blood* October 18, 2011; DOI 10.1182/blood-2011-06-

- P-210. Zhang P, Chen BJ, Chao NJ. Prevention of GVHD without losing GVL effect; windows of opportunity. *Immunol Res* 2011;49:49-55
- P-211. Chao NJ. Control of GVHD: its in our DNA! *Blood* 2012;119:1102-110
- P-212. Hye Ryun Lee, Jeong Su Park, Sue Shin, Eun Youn Roh, Jong Hyun Yoon, Kyou Sup Han, Byung Jae Kim, Robert W. Storms, Nelson J. Chao. Increased numbers of total nucleated and CD34+ cells in blood group O cord blood: an analysis of neonatal innate factors in the Korean population. *Transfusion* 2012;52:76
- P-213. Phuong L. Doan, J. Lauren Russell, Heather A. Himburg, Katherine Helms, Jeffrey Harris, Joseph Lucas, Kirsten Holshausen, Sarah K. Meadows, Pamela Daher, Laura B. Jeffords, Nelson J. Chao, David G. Kirsch, John P. Chute. Tie2⁺ Bone Marrow Endothelial Cells Regulate Hematopoietic Stem Cell Regeneration Following Radiation Injury. *Stem Cells* 2012; 10.1002/stem.1275
- P-214. Heather A. Himburg, Jeffrey R. Harris, Takahiro Ito, Pamela Daher, J. Lauren Russell, Mable Quarmyne, Phuong L. Doan, Katherine Helms, Mai Nakamura, Emma Fixsen, Gonzalo Herradon, Tannishtha Reya, Nelson J. Chao, Sheila Harroch, John P. Chute. Pleiotrophin Regulates the Retention and Self-Renewal of Hematopoietic Stem Cells in the Bone Marrow Vascular Niche. *Cell Reports* 2012; 2; 964-975
- P-215. Todd V. Brennan, Liwen Lin, Xiaopei Huang, Diana M. Cardona, Zhiguo Li, Keith Dredge, Nelson J. Chao, and Yiping Yang. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD following allogeneic stem cell transplantation. *Blood* 2012;120:2899-2908.
- P-216. Kanda, Junya, et al. "Immune Recovery in Adult Patients Following Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation." *Biology of Blood and Marrow Transplantation* (2012). 2012;11; 1664-1676
- P-217. Chao, Nelson. "You Cannot Improve What You Do Not Measure." *Biology of Blood and Marrow Transplantation* 18.10 (2012): 1467-1468.
- P-218. Chen BJ, Jiao Y, Zhang P, Sun AY, Pitt GS, et al. (2013) Long-Term In Vivo Imaging of Multiple Organs at the Single Cell Level. *PLoS ONE* 8(1): e52087. doi:10.1371/journal.pone.0052087
- P-219. MBBS, M., Le-Rademacher, J., Barker, J. N., & Chao, N. (2012). Double Unit Grafts Successfully Extend the Application of Umbilical Cord Blood Transplantation in Adults with Acute Leukemia Running title: Extending Application of Cord Blood Transplant. *Blood* doi:10.1182/blood-2012-08-449108
- P-220. Spasojevic, Ivan, L. R. da Costa, Mitchell E. Horwitz, Gwynn D. Long, Keith M. Sullivan, John P. Chute, Cristina Gasparetto, Ashley Morris, Nelson J. Chao, and David A. Rizzieri. "Mini Test Dose of Intravenous Busulfan (Busulfex (®)) in Allogeneic Non-Myeloablative Stem Cell Transplantation, Followed by Liquid Chromatography Tandem-Mass Spectrometry." *Cancer investigation* 2012;30(9):679-82. doi: 10.3109/07357907.2012.726386.
- P-221. Coleman, C. Norman, Steven Adams, Carl Adrianopoli, Armin Ansari, Judith L. Bader, Brooke Buddemeier, J. Jaime Caro et al. "Medical planning and response for a nuclear detonation: a practical guide." *Biosecurity and bioterrorism: biodefense strategy, practice, and science* 10, no. 4 (2012): 346.
- P-222. Kang, Yubin, and Nelson J. Chao. "Strategies to Enhance Hematopoietic Stem Cell Engraftment Following Transplantation." *Novel Developments in Stem Cell Mobilization* (2012): 439-456.

P-223. Zhou, Dunhua, Divino Deoliveira, Yubin Kang, Seung S. Choi, Zhiguo Li, Nelson J. Chao, and Benny J. Chen. "Insulin-Like Growth Factor 1 Mitigates Hematopoietic Toxicity After Lethal Total Body Irradiation." *International Journal of Radiation Oncology* Biology* Physics* (2012).[dx.doi.org/10.1016/j.ijrobp.2012.08.014](https://doi.org/10.1016/j.ijrobp.2012.08.014)

P-224. Zhang, Ping, Jieying Wu, Divino Deoliveira, Nelson J. Chao, and Benny J. Chen. "Allo-specific CD4+ Effector Memory T Cells Do Not Induce Graft-versus-Host Disease in Mice." *Biology of Blood and Marrow Transplantation* (2012).

P-225. Sung, Anthony D., and Nelson J. Chao. "Concise Review: Acute Graft-Versus-Host Disease: Immunobiology, Prevention, and Treatment." *Stem Cells Translational Medicine* 2.1 (2013): 25-32.

P-226. Doan PL, Himburg HA, Helms K, Russell JL, Fixsen E, Quarmyne M, Harris JR, Deoliveira D, Sullivan JM, Chao NJ, Kirsch DG, Chute JP. Epidermal growth factor regulates hematopoietic regeneration after radiation injury *Nature Medicine* 2013, 19, 295-304 doi:10.1038/nm.3070

P-227. Lento W, Ito T, Zhao C, Harris JR, Huang W, Jiang C, Owzar K, Piryani S, Racciopi L, Chao N, Reya T. Loss of β -catenin triggers oxidative stress and impairs hematopoietic regeneration. *Genes & Dev.* 2014. 28: 995-1004

P-228. Horwitz ME, Chao NJ, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, McDonald C, Waters-Pick B, Stiff P, Wease S, Peled A, Snyder D, Cohen EG, Shoham H, Landau E, Friend E, Peleg I, Aschengrau D, Yackoubov D, Kurtzberg J, Peled T. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. *J Clin Invest.* Jul 1, 2014; 124(7): 3121–3128. PMID: PMC4071379

P-229. Allen JL, Tata PV, Fore MS, Wooten J, Rudra S, Deal AM, Sharf A, Hoffert T, Roehrs PA, Shea TC, Serody JS, Richards KL, Jagasia M, Lee SJ, Rizzieri D, Horwitz ME, Chao NJ, and Sarantopoulos S. Increased BCR responsiveness in B cells from patients with chronic GVHD. *Blood* 2014; 123: 2147-2154.

P-230. Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA. Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. *Biol Blood Marrow Transplant* 2014;20:257-263.

P-231. McClune BL, Kwang Woo Ahn, Hai-Lin Wang, Joseph H. Antin, Andrew S. Artz, Jean-Yves Cahn, Abhinav Deol, César O. Freytes, Mehdi Hamadani, Leona A. Holmberg, Madan H. Jagasia, Ann A. Jakubowski, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Alan M. Miller, Richard Olsson, Tanya L. Pedersen, Joseph Pidala, Michael A. Pulsipher, Jacob M. Rowe, Wael Saber, Koen W. van Besien, Edmund K. Waller, Mahmoud D. Aljurf, Görgun Akpek, Ulrike Bacher, Nelson J. Chao, Yi-Bin Chen, Brenda W. Cooper. Allotransplantation for Patients Age ≥ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. *Biol Blood Marrow Transplant* 2014;20:960-968.

P-232. Rein LM, Chao NJ. WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. *Expert Opinion on Investigational Drugs*, March 2014, Vol. 23, No. 3 : Pages 417-426

P-233. Chao NJ. How I treat Sinusoidal Obstructive Syndrome. *Blood* 2014;123:4023-4036

Matthew D. Belley, Chu Wang, Giao Nguyen, Rathnayaka Gunasingha, Nelson J. Chao, Benny J. Chen, Mark W. Dewhirst and Terry T. Yoshizumi. Toward an organ based dose prescription method for the improved accuracy of murine dose in orthovoltage x-ray irradiators. *Med. Phys.* 41, 034101 (2014)

P-234. Heather A. Himgurg, Xiao Yan, Phuong L. Doan, Mamle Quarmyne, Eva Micewicz, William McBride, Nelson J. Chao, Dennis J. Slamon and John P. Chute. Pleiotrophin mediates hematopoietic regeneration via activation of RAS. *J Clin Invest.* 2014;124(11):4753–4758. doi:10.1172/JCI76838.

P-235. Sally Arai, Mukta Arora, Tao Wang, et al. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation – A Report from CIBMTR. *BBMT* doi:10.1016/j.bbmt.2014.10.021

P- 236. Lucas J, Dressman HK, Suchindran S, Nakamura M, Chao NJ, Himgurg H, Minor K, Phillips G, Ross J, Abedi M, Terbrueggen R, Chute JP. A Translatable Predictor of Human Radiation Exposure. *Plos One* DOI: 10.1371/journal.pone.0107897

P-237. Chu Wang, Matthew D. Belley, Nelson J. Chao, Mark W. Dewhirst and Terry Yoshizumi. Verification of a novel method for tube voltage constancy measurement of orthovoltage x-ray irradiators. *Med. Phys.* 41, 084101 (2014); <http://dx.doi.org/10.1118/1.4889778>

P-238. Chang-Lung Lee, William E. Lento, Katherine D. Castle, Nelson J. Chao, and David G. Kirsch (2014) Inhibiting Glycogen Synthase Kinase-3 Mitigates the Hematopoietic Acute Radiation Syndrome in Mice. *Radiation Research*: May 2014, Vol. 181, No. 5, pp. 445-451.

P-239. Coleman, C., Silvia C. Formenti, Tim R. Williams, Daniel C. Petereit, Khee Chee Soo, John Wong, Nelson Chao et al. "The International Cancer Expert Corps: a unique approach for sustainable cancer care in low and lower-middle income countries." *Frontiers in Oncology* 4 (2014): 333.

P-240. Tuchman, Sascha A., Wendi A. Bacon, Li-Wen Huang, Gwynn Long, David Rizzieri, Mitchell Horwitz, John P. Chute et al. "Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma." *Journal of Clinical Apheresis* (2014).

P-241. Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Chao NJ, Clynes RA, Sarantopoulos S, Blazar BR. Targeting Syk Activated B-cells in murine and human chronic graft-versus-host disease. *Blood* 2015 Apr 7. pii: blood-2014-08-595470.

P-242. David J. Brenner, Nelson J. Chao, MD, Joel S. Greenberger, Chandan Guha, William H. McBride, Harold M. Swartz, Jacqueline P. Williams. Are We Ready for a Radiological Terrorist Attack Yet? Report from the CMCR Network. DOI: <http://dx.doi.org/10.1016/j.ijrobp.2015.02.042>

BOOKS

B-1. Chao NJ. *Graft-versus-Host Disease: Past, Present, and Future*. RP Landes Company, Austin, TX, 1994.

B-2 Chao NJ. *Graft-versus-Host Disease*. Second Edition, RP Landes Company, Austin, TX, 1998.

LETTERS

L1. Chao NJ, Long GD, Negrin RS, Schriber JR, Raimondi CM, Brown SL, and Blume KG. G-CSF and peripheral blood progenitor cells. The Lancet, 339:1410, 1992.

L-2. Chao NJ, Blume KG, Forman SJ, and Snyder DS. Long-term follow-up of allogeneic BMT for Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 88:3353-4 [letter], 1995.

EDITORIALS

E1. Chao NJ and Blume KG. Bone marrow transplantation: What is the question? Annals of Internal Medicine 113:340-341, 1990.

E2. Chao NJ and Blume KG. Surviving the Cure. Bone Marrow Transplantation Reviews 2:14, 1992.

BOOK CHAPTERS/REVIEWS

C1. Blume KG, Schmidt GM, Chao NJ, Amylon MD, Konrad PN and Forman SJ. Bone marrow transplantation acute lymphoblastic leukemia. In: Acute Lymphoblastic Leukemia R.P. Gale and D. Hoelzer, eds. Wiley-Liss, New York, 1989 pg. 279-283.

C-2. Blume KG, Schmidt GM, Chao NJ, Krance RA, Amylon MD and Forman SJ. Bone marrow transplantation from histocompatible sibling donors for patients with acute lymphoblastic leukemia. Bone Marrow Transplantation 4(Suppl.2):18, 1989.

C-3. Chao NJ, Long GD, Negrin RS, Horning SJ and Blume KG. Bone Marrow Transplantation: the Stanford experience. In: Clinical Transplants Ed.: Terasaki, P., UCLA Tissue Typing Laboratory, Los Angeles, CA, 1990.

C-4. Chao NJ, and Blume KG. Reconstitution of hematopoiesis following allogeneic bone marrow transplantation. In: High Dose Cancer Therapy: Pharmacology, Hematopoietins and Stem Cells. Eds: Armitage, J.O., Antman, K.H., Williams and Wilkens, Baltimore, MD 1991.

C-5. Chao NJ. Hematology/Oncology (Section VII). In Medicine. Eds: Fishman, M.C., Hoffman, A.R., Klausner, R.D., Thaler, M.S., J.B. Lippincott, Philadelphia, PA, 1991.

C-6. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P and Blume KG. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Annals of Oncology 2 (Suppl.1):47-50, 1991.

C-7. Chao NJ, Aihara M, Kuhl J-S, Blume KG, and Sikic BI. Purging multidrug resistant cells from the bone marrow. In: Advances in Bone Marrow Purging and Processing, Eds: Gross, S. and Gee, A.P. Wiley-Liss, New York, 13-24, 1992.

C-8. Kuhl J-S, Sikic BI, Blume KG, and Chao NJ. Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. In: Advances in Bone Marrow Purging and Processing, Eds: Gross, S. and Gee, A.P. Wiley-Liss, New York, 25-34, 1992.

- C-9. Chao NJ. Graft-versus-host disease following allogeneic bone marrow transplantation. Current Opinion in Immunology, 4:571-576, 1992.
- C-10. Chao NJ, Hoppe RT, Forman SJ, and Blume KG. Total body irradiation and chemotherapy for bone marrow transplantation. In: Chemoradiation: an Integrated Approach in Oncology Eds.: John, M.J., Flam, M.S., Legha, S.S. and Phillips, T.L., Lea & Febiger, Philadelphia, 1993.
- C-11. Blume KG, Snyder DS, Chao NJ, and Forman SJ. Myeloablative regimens containing high dose etoposide followed by allogeneic or autologous bone marrow transplantation for hematologic malignancies. Acute Leukemias IV, 39-42, 1993.
- C-12. Chao NJ and Forman SJ. Allogeneic Bone Marrow Transplantation for Acute Lymphoblastic Leukemia. In: Bone Marrow Transplantation. Eds. Forman, S.J., Thomas, E.D. Blume, K.G., Blackwell Scientific Publications, Inc., New York, 1994.
- C-13. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, and Blume KG. The Stanford experience with high-dose etoposide-containing regimens in intermediate and high-grade non-Hodgkin's lymphoma. In Zander, Barlogie, (eds): Autologous Bone Marrow Transplantation for Hodgkin's Disease, Non-Hodgkin's Lymphoma and Multiple Myeloma. New York, NY, Springer-Verlag, 1993, pp. 77-82.
- C-14. Blume KG, Long GD, Negrin RS, Chao NJ, Kusnierz-Glaz C, and Amylon MD. The role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation, 14 (Suppl 4) S9-10, 1994.
- C-15. Chao NJ, and Blume KG. Reconstitution of hematopoiesis following allogeneic bone marrow transplantation. In: High Dose Cancer Therapy: Pharmacology, Hematopoietins and Stem Cells. Eds: Armitage, J.O., Antman, K.H., Williams and Wilkens, Baltimore, MD., 1995.
- C-16. Chao NJ and Deeg HJ. In vivo prevention and treatment of GVHD. In Graft-versus-Host Disease. Eds: Ferrara, J.L.M., Deeg, H.J., and Burakoff S., Marcel Dekker, New York, NY, 1995.
- C-17. Chao NJ. Prevention and treatment of graft-versus-host disease. In On Call in...Bone Marrow Transplantation. Ed: Burt RK, Deeg J, Santos G. R. G. Landes, Austin, TX, 1995.
- C-18. Chao NJ, and Sackstein R. Venous-occlusive Disease. In The Kidney in Liver Disease. Ed: Epstein M. Elsevier, New York, 1995.
- C-19. Chao NJ and Schlegel PG. Prevention and treatment of graft-versus-host disease. Ann NY Acad Sci, 770:130-140, 1995.
- C-20. Chao NJ. Mobilization of peripheral blood progenitor cells by hematopoietic growth factors. Canadian Journal of Oncology, 5 (Suppl 1): 43-46, 1995.
- C-21. Chao NJ. Transplantation Immunology. In Textbook of Internal Medicine Ed: Kelley WN., J.B. Lippincott, New York, NY, 1997.
- C-22. Chao, NJ. Graft-versus-Host Disease. In Up to Date. Ed Rose B. Wellesley, MA, 1998.

- C-23. Chao, NJ. Pharmacological Prevention of Graft-vs-Host disease. In: Bone Marrow Transplantation. Eds. Forman, S.J., Thomas, E.D. Blume, K.G. Blackwell Scientific Publications, Inc., New York, 1998.
- C-24 Rizzieri DA, Long GD, Chao NJ. Leukemia. In Hospital Medicine Ed: Wachter RM, Goldman L, Hollander H. Lippincott Williams & Wilkins, Philadelphia, PA, 2000.
- C-25 Goggins T, Chao NJ. Umbilical Cord Hematopoietic Stem Cell Transplantation in Stem Cell Transplantation for Hematologic Malignancies Ed: Soiffer R. Humana Press, Totowa NJ. pp 391-414. 2004.
- C-26 Chao NJ, Holler E, Deeg HJ. Prophylaxis and Treatment of Acute Graft-vs.-Host Disease. In: Graft-vs.-Host Disease Ed: Ferrara JLM, Cooke KR, Deeg HJ. Marcel Dekker Press New York, NY 2005
- C-23. Chao, NJ. Pharmacological Prevention of Graft-vs-Host disease. In: Thomas' Hematopoietic Cell Transplantation. Eds. Appelbaum F, Forman, S.J., Negrin RS. Blume, K.G. Blackwell Scientific Publications, Inc., New York, 2008.

Research Support

NIH – 1U19 AI067798-01 (Chao, Nelson J., PI)

08/31/2010 – 07/30/2014

Centers for Medical Countermeasures Against Radiation

The broad and long term objectives of this research application focuses on rapid biodosimetry and mitigation of radiation injury as well as advancing education in this area.

R21/33-AI080525 (Chao, Nelson J.)

07/01/2008 - 06/30/2013

NIH

The objective of this project will be to establish the model and the biological monitoring of the impact of combined radiation and dermal wound injuries. The R33 followed on studies will optimize therapeutic responses and extend the combined injury model to include burns.

P01 CA47741 (Chao, Nelson)

09/30/2009 – 06/30/2014

NIH/NCI

Novel Approaches for Stem Cell Transplantation

The long-term objective of this project is to improve the outcome following high dose chemotherapy for hematological diseases. The project related to this grant studies the outcome following allogeneic stem cell transplantation for leukemias and lymphomas.

01/01/2010 - 12/31/2014

5-P30-CA14236-28 (Lyerly, Kim, PI)

NIH/NCI

Comprehensive Cancer Center Core Grant (Bone Marrow Transplantation Program, Program Leader)

The major goals of this project are to integrate program coordinators with specific research nurse/data management support under the administrative direction of the clinical trials office as one shared resource.